Aquestive Therapeutics Files 8-K for Bylaws and Exhibits
Ticker: AQST · Form: 8-K · Filed: Oct 16, 2024 · CIK: 1398733
| Field | Detail |
|---|---|
| Company | Aquestive Therapeutics, Inc. (AQST) |
| Form Type | 8-K |
| Filed Date | Oct 16, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, filing, financials
Related Tickers: AQST
TL;DR
AQST filed an 8-K for corporate updates and financials.
AI Summary
Aquestive Therapeutics, Inc. filed an 8-K on October 16, 2024, to report amendments to its articles of incorporation or bylaws and to file financial statements and exhibits. The company, formerly known as MonoSol Rx, Inc., is incorporated in Delaware and headquartered in Warren, NJ.
Why It Matters
This filing indicates routine corporate updates and the submission of necessary financial documentation, which is standard for publicly traded companies.
Risk Assessment
Risk Level: low — The filing pertains to routine corporate actions and financial statement submissions, not a material event impacting the company's operations or financial health.
Key Numbers
- 001-38599 — SEC File Number (Identifies the company's filing with the SEC)
- 82-3827296 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Aquestive Therapeutics, Inc. (company) — Registrant
- MonoSol Rx, Inc. (company) — Former company name
- October 16, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Warren, NJ (location) — Principal executive offices
FAQ
What specific amendments were made to Aquestive Therapeutics' articles of incorporation or bylaws?
The filing indicates amendments were made, but the specific details of these amendments are not provided in the summary information of the 8-K.
What financial statements and exhibits are being filed with this 8-K?
The filing states that financial statements and exhibits are being filed, but the specific content of these documents is not detailed in the provided text.
When was Aquestive Therapeutics, Inc. formerly known as MonoSol Rx, Inc.?
The date of the name change from MonoSol Rx, Inc. to Aquestive Therapeutics, Inc. was May 7, 2007.
What is the principal executive office address for Aquestive Therapeutics, Inc.?
The principal executive offices are located at 30 Technology Drive, Warren, NJ 07059.
What is the fiscal year end for Aquestive Therapeutics, Inc.?
The company's fiscal year ends on December 31.
Filing Stats: 552 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-10-16 17:16:29
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share AQST Nasdaq Global Market I
Filing Documents
- aqst-20241016.htm (8-K) — 28KB
- aquestiveamendedandresta.htm (EX-3.1) — 75KB
- aquestiveamendedandresta001.jpg (GRAPHIC) — 253KB
- aquestiveamendedandresta002.jpg (GRAPHIC) — 308KB
- aquestiveamendedandresta003.jpg (GRAPHIC) — 330KB
- aquestiveamendedandresta004.jpg (GRAPHIC) — 332KB
- aquestiveamendedandresta005.jpg (GRAPHIC) — 356KB
- aquestiveamendedandresta006.jpg (GRAPHIC) — 318KB
- aquestiveamendedandresta007.jpg (GRAPHIC) — 316KB
- aquestiveamendedandresta008.jpg (GRAPHIC) — 268KB
- aquestiveamendedandresta009.jpg (GRAPHIC) — 275KB
- aquestiveamendedandresta010.jpg (GRAPHIC) — 269KB
- aquestiveamendedandresta011.jpg (GRAPHIC) — 272KB
- aquestiveamendedandresta012.jpg (GRAPHIC) — 255KB
- aquestiveamendedandresta013.jpg (GRAPHIC) — 334KB
- aquestiveamendedandresta014.jpg (GRAPHIC) — 195KB
- aquestiveamendedandresta015.jpg (GRAPHIC) — 108KB
- 0001628280-24-042948.txt ( ) — 6024KB
- aqst-20241016.xsd (EX-101.SCH) — 2KB
- aqst-20241016_lab.xml (EX-101.LAB) — 22KB
- aqst-20241016_pre.xml (EX-101.PRE) — 13KB
- aqst-20241016_htm.xml (XML) — 3KB
03
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On October 16, 2024, the Board of Directors (the "Board") of Aquestive Therapeutics, Inc. (the "Company"), in connection with its periodic review of corporate governance matters, approved amendments, effective immediately, to the Company's Amended and Restated Bylaws, as amended (the "Bylaws"). The Bylaws supersede the previously existing Amended and Restated Bylaws of the Company (the "Prior Bylaws"). Specifically, Article I, Section 11 of the Prior Bylaws, which sets forth requirements for stockholder nominations of candidates for election to the Board, has been amended to shorten the look-back period for required information concerning agreements, arrangements and understandings relating to stockholder nominations from three years to two years. In addition, the Prior Bylaws were amended to make certain technical and modernizing changes, namely, to replace all references to "chairman" with "chair." The foregoing description is qualified in its entirety by reference to the full text of the Bylaws which are attached hereto as Exhibit 3.1 and incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 3.1 Amended and Restated Bylaws of Aquestive Therapeutics, Inc. adopted on October 16, 2024. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 16, 2024 Aquestive Therapeutics, Inc. By: /s/ A. Ernest Toth, Jr Name: A. Ernest Toth, Jr. Title: Chief Financial Officer